look news india
There are some discoveries in the history of medical science that revive the sleeping hopes of both doctors and patients suffering from fatal diseases. One such big and revolutionary change is being seen in the treatment of pancreatic cancer. A new experimental tablet was presented at the annual meeting of the ‘American Society of Clinical Oncology’ (ASCO) held in Chicago recently. Daraxonrasib The results of the Phase III clinical trial have been presented, which has also been published prominently in the prestigious ‘New England Journal of Medicine’.
The results of this study show that this drug is not only capable of increasing the life span of patients suffering from advanced pancreatic cancer, but it is also much safer and more comfortable than traditional chemotherapy.
After all, why is pancreatic cancer considered so deadly?
Pancreatic cancer is considered one of the most aggressive and dangerous cancers in the world. It starts with abnormal growth of cells in the pancreas, located just behind the lower stomach. The pancreas is a very important part of our body, which produces enzymes that digest food and hormones like insulin that control blood sugar.
The scariest thing about this cancer is that it In 80 to 85 percent of cases, no symptoms are visible in the initial stages.. By the time the disease is caught, it has spread to the rest of the body. Common symptoms include persistent pain in the stomach or back, sudden weight loss, loss of appetite, jaundice (yellowing of the skin and eyes), dark urine, and sudden uncontrolled diabetes (blood sugar). This is the reason why the survival rate of its patients for 5 years is only around 10 percent.
Daraxonerasib vs Chemotherapy: Understand how big the difference is in statistics
A total of 500 advanced stage patients were included in this large clinical trial. Of these, 248 patients were given Daraxonrasib tablets taken once daily, while the remaining 252 patients were treated with conventional chemotherapy.
The results that emerged after the trial surprised cancer experts:
‘Molecular Glue’ Technology: Know how this drug works
In more than 90% of pancreatic cancer cases, a specific mutated protein is responsible for rapid tumor growth and uncontrolled cell division. KRAS gene mutation It is said. Normally this protein acts like an ‘on-off’ switch for the growth of cells, but in the case of cancer, it always gets stuck in the ‘on’ position, causing the cancer to continue spreading.
? Decades of wait is over
Scientists have been searching for a way to block this stubborn protein for decades, but have been unsuccessful due to its complex structure. Daraxonerasib is a type of drug ‘Molecular Glue’ Works like. It sticks directly to that mutated protein and completely blocks the signal to the cancer cells. As soon as the signal stops, tumor growth stops and cancer cells start dying.
Comfort and better quality of life for patients
The biggest challenge during cancer treatment is the dangerous side effects of chemotherapy such as hair loss, severe weakness, vomiting and nerve weakness. But in the case of Daraxonrasib, patients have got relief from these problems to a great extent. Its most common side effects are mild skin rashes or mouth ulcers, which can be easily treated with medicines.
Since it is a generic pill, patients do not need to make frequent trips to the hospital or spend hours in the chemotherapy ward. They can live a better and pain-free life among their families by staying at their home. Although this drug is still undergoing regulatory approvals (such as FDA approval) before it can be fully marketed, doctors believe that it is going to become the new standard of treatment for pancreatic cancer in the future.
